Quick Answer
INSMED Inc reported Total Revenue of $606.42 million for fiscal year 2025.
INSMED Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $606.42M +66.7% |
$363.71M +19.2% |
$305.21M +24.4% |
$245.36M +30.2% |
$188.46M +14.6% |
$164.41M +20.5% |
| Revenue (ASC 606) | $606.42M +66.7% |
$363.71M +19.2% |
$305.21M +24.4% |
$245.36M +30.2% |
$188.46M +14.6% |
$164.41M +20.5% |
| Net Income | -$1.28B -39.7% |
-$913.77M -21.9% |
-$749.57M -55.7% |
-$481.53M -10.8% |
-$434.65M -47.8% |
-$294.09M -15.6% |
| Diluted EPS | -$6.42 -15.3% |
-$5.57 -4.3% |
-$5.34 -36.6% |
-$3.91 -0.8% |
-$3.88 -28.9% |
-$3.01 +0.0% |
| Total Assets | $2.26B +11.8% |
$2.03B +52.3% |
$1.33B -19.7% |
$1.66B +33.2% |
$1.24B +56.2% |
$796.15M +7.3% |
| Cash and Equivalents | $510.44M -8.0% |
$555.03M +15.1% |
$482.37M -55.1% |
$1.07B +49.8% |
$716.78M +34.5% |
$532.76M +9.3% |
| Long-Term Debt | $540.96M -51.0% |
$1.10B -4.5% |
$1.16B +2.7% |
$1.13B +98.6% |
$566.59M +59.0% |
$356.32M +6.1% |
| Stockholders Equity | $738.98M +158.9% |
$285.38M +186.0% |
-$331.92M -477.4% |
$87.95M -78.6% |
$410.47M +48.8% |
$275.88M +5.4% |
| R&D Expense | $771.09M +28.9% |
$598.37M +4.8% |
$571.01M +43.6% |
$397.52M +45.7% |
$272.74M +50.6% |
$181.16M +37.5% |
| Operating Income | -$1.25B -42.0% |
-$878.25M -23.8% |
-$709.63M -55.2% |
-$457.32M -21.9% |
-$375.09M -41.4% |
-$265.23M -12.7% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 214.26M +19.4% |
179.38M +21.2% |
147.98M +9.1% |
135.65M +14.2% |
118.74M +15.5% |
102.76M +14.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $142.34M | +52.4% | +32.5% |
| Revenue (ASC 606) | September 30, 2025 | $142.34M | +52.4% | +32.5% |
| Net Income | September 30, 2025 | -$370.02M | -67.8% | -15.0% |
| Diluted EPS | September 30, 2025 | -$1.75 | -37.8% | -2.9% |
| Total Assets | September 30, 2025 | $2.36B | +15.0% | -4.8% |
| Cash and Equivalents | September 30, 2025 | $334.76M | -27.5% | -73.9% |
| Long-Term Debt | September 30, 2025 | $539.72M | -43.5% | +0.2% |
| Stockholders Equity | September 30, 2025 | $945.57M | +95.6% | -24.3% |
| R&D Expense | September 30, 2025 | $186.41M | +23.6% | +5.2% |
| Operating Income | September 30, 2025 | -$366.00M | -71.5% | -17.0% |
| Gross Profit | September 30, 2020 | $33.02M | +1.8% | +1.5% |
| Shares Outstanding | September 30, 2025 | 212.58M | +18.9% | +0.7% |
- INSMED Inc reported Total Revenue of $606.42 million for fiscal year 2025.
- INSMED Inc showed an increase of +66.7% in Total Revenue compared to the prior fiscal year.
- INSMED Inc reported Revenue (ASC 606) of $606.42 million for fiscal year 2025.
- INSMED Inc showed an increase of +66.7% in Revenue (ASC 606) compared to the prior fiscal year.
- INSMED Inc reported Net Income of -$1.28 billion for fiscal year 2025.
- INSMED Inc showed a decrease of -39.7% in Net Income compared to the prior fiscal year.
- INSMED Inc reported Diluted EPS of $6.42 per share (loss) for fiscal year 2025.
- INSMED Inc showed a decrease of -15.3% in Diluted EPS compared to the prior fiscal year.
- INSMED Inc reported Total Assets of $2.26 billion for fiscal year 2025.
- INSMED Inc showed an increase of +11.8% in Total Assets compared to the prior fiscal year.
- INSMED Inc reported Cash and Equivalents of $510.44 million for fiscal year 2025.
- INSMED Inc showed a decrease of -8.0% in Cash and Equivalents compared to the prior fiscal year.
- INSMED Inc reported Long-Term Debt of $540.96 million for fiscal year 2025.
- INSMED Inc showed a decrease of -51.0% in Long-Term Debt compared to the prior fiscal year.
- INSMED Inc reported Stockholders Equity of $738.98 million for fiscal year 2025.
- INSMED Inc showed an increase of +158.9% in Stockholders Equity compared to the prior fiscal year.
- INSMED Inc reported R&D Expense of $771.09 million for fiscal year 2025.
- INSMED Inc showed an increase of +28.9% in R&D Expense compared to the prior fiscal year.
- INSMED Inc reported Operating Income of -$1.25 billion for fiscal year 2025.
- INSMED Inc showed a decrease of -42.0% in Operating Income compared to the prior fiscal year.
- INSMED Inc reported Gross Profit of $112.25 million for fiscal year 2019.
- INSMED Inc showed an increase of +1414.5% in Gross Profit compared to the prior fiscal year.
- INSMED Inc reported Shares Outstanding of 214.26 million shares for fiscal year 2025.
- INSMED Inc showed an increase of +19.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: